Added value of whole-genome sequencing for management of highly drug-resistant TB

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 4, 2014, Pages 1198-1202

  Outhred, Alexander C ^a,b,c   Jelfs, Peter ^b,d   Suliman, Basel ^b,d   Hill Cawthorne, Grant A ^a   Crawford, Archibald B H ^e   Marais, Ben J ^a,c   Sintchenko, Vitali ^a,b,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Institute of Clinical Pathology and Medical Research NSW Health Pathology   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e LIVERPOOL HOSPITAL   (Australia)

Author keywords

Extensively drug resistant; MDR; Multidrug resistant; XDR

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; COTRIMOXAZOLE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADD ON THERAPY; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ASCITES; AUSTRALIA; BACTERIAL GENOME; BACTERIUM CULTURE; CACHEXIA; CASE REPORT; COMPUTER MODEL; COUGHING; DIGITAL CLUBBING; DIRECTLY OBSERVED THERAPY; DISEASE COURSE; DISEASE FREE INTERVAL; DJIBOUTI; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEVER; FOLLOW UP; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG HEMORRHAGE; MAJOR DEPRESSION; MALE; MIGRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PHENOTYPE; SPUTUM CULTURE; SPUTUM CYTODIAGNOSIS; SPUTUM SMEAR; THORAX RADIOGRAPHY; WEIGHT GAIN; DNA SEQUENCE; DRUG EFFECTS; EVALUATION STUDY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETICS; GENOTYPING TECHNIQUE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PROCEDURES;

ADULT; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENOME, BACTERIAL; GENOTYPING TECHNIQUES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; SEQUENCE ANALYSIS, DNA;

EID: 84926453126     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku508     Document Type: Article

References (27)

1. Abubakar I, Zignol M, Falzon D et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013; 13: 529-39.
2. World Health Organization. Global Tuberculosis Report 2013. Geneva, Geneva: WHO, 2013.
3. Chihota VN, Müller B, Mlambo CK et al. Population structure of multi-and extensively drug-resistant Mycobacterium tuberculosis strains in South Africa. J Clin Microbiol 2012; 50: 995-1002.
4. Klopper M, Warren RM, Hayes C et al. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis 2013; 19: 449-55.
5. Pietersen E, Ignatius E, Streicher EM et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014; 383: 1230-9.
6. Goloubeva V, Lecocq M, Lassowsky P et al. Evaluation of Mycobacteria Growth Indicator Tube for direct and indirect drug susceptibility testing of Mycobacterium tuberculosis from respiratory specimens in a Siberian prison hospital. J Clin Microbiol 2001; 39: 1501-5.
7. Sandgren A, Strong M, Muthukrishnan P et al. Tuberculosis drug resistance mutation database. PLoS Med 2009; 6: e1000002.
8. Malik S, Willby M, Sikes D et al. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One 2012; 7: e39754.
9. Maruri F, Sterling TR, Kaiga AWet al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 2012; 67: 819-31.
10. Georghiou SB, Magana M, Garfein RS et al. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 2012; 7:e33275.
11. Nebenzahl-Guimaraes H, Jacobson KR et al. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2014; 69: 331-42.
12. Schön T, Juréen P, Giske CG et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009; 64: 786-93.
13. Köser CU, Summers DK, Archer JAC. Role of the dihydrofolate reductase DfrA (Rv2763c) in trimethoprim-sulfamethoxazole (co-trimoxazole) resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010; 54: 4951-2.
14. Fivian-Hughes AS, Houghton J, Davis EO. Mycobacterium tuberculosis thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA deletion confers resistance to p-aminosalicylic acid. Microbiology 2012; 158: 308-18.
15. Caminero JA, Sotgiu G, Zumla A et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-9.
16. Lorenzo SD, Alffenaar JW, Sotgiu G et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-92.
17. Sotgiu G, Centis R, D'Ambrosio L et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-42.
18. Skripconoka V, Danilovits M, Pehme L et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-400.
19. Diacon AH, Donald PR, Pym A et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis:long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-6.
20. LoBue P, Sizemore C, Castro KG. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. Morb Mortal Wkly Rep 2009; 58: 1-43.
21. Schürch AC, Kremer K, Kiers A et al. The tempo and mode of molecular evolution of Mycobacterium tuberculosis at patient-to-patient scale. Infect Genet Evol 2010; 10: 108-14.
22. Gardy JL, Johnston JC, Ho Sui SJ et al. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. New Engl J Med 2011; 364: 730-9.
23. Roetzer A, Diel R, Kohl TA et al. Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak:a longitudinal molecular epidemiological study. PLoS Med 2013; 10: e1001387.
24. Walker TM, Ip CL, Harrell RH et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis 2013; 13: 137-46.
25. Pérez-Lago L, Comas I, Navarro Yet al. Whole genome sequencing analysis of intrapatient microevolution in Mycobacterium tuberculosis: potential impact on the inference of tuberculosis transmission. J Infect Dis 2014; 209: 98-108.
26. Lau RWT, Ho P-L, Kao RYTet al.Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74. Antimicrob Agents Chemother 2011; 55: 608-14.
27. Kim H, Nakajima C, Yokoyama K et al. Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance. Antimicrob Agents Chemother 2011; 55: 3661-7.